Millennium Management LLC Makes New $262,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Millennium Management LLC acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 151,614 shares of the company's stock, valued at approximately $262,000. Millennium Management LLC owned approximately 0.07% of Taysha Gene Therapies as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Hsbc Holdings PLC boosted its stake in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after acquiring an additional 8,076 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in Taysha Gene Therapies by 43.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company's stock valued at $55,000 after acquiring an additional 9,494 shares during the last quarter. Geode Capital Management LLC boosted its stake in Taysha Gene Therapies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock valued at $6,182,000 after acquiring an additional 9,591 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after acquiring an additional 11,390 shares during the last quarter. Finally, Ground Swell Capital LLC bought a new position in Taysha Gene Therapies during the 4th quarter valued at $25,000. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Stock Down 4.2%

NASDAQ TSHA traded down $0.11 during trading on Friday, reaching $2.54. The company's stock had a trading volume of 2,460,645 shares, compared to its average volume of 3,091,477. The business has a 50-day moving average price of $2.18 and a 200-day moving average price of $1.93. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $4.07. The stock has a market capitalization of $545.24 million, a PE ratio of 4.03 and a beta of 1.04.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. During the same period in the previous year, the company earned ($0.10) earnings per share. On average, research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Paul B. Manning bought 750,000 shares of the stock in a transaction dated Friday, May 30th. The shares were acquired at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the acquisition, the insider now owns 2,841,704 shares in the company, valued at $7,814,686. This trade represents a 35.86% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 3.78% of the company's stock.

Wall Street Analysts Forecast Growth

TSHA has been the topic of a number of research analyst reports. Canaccord Genuity Group increased their price objective on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, June 3rd. JMP Securities increased their price objective on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research note on Thursday, May 29th. Cantor Fitzgerald restated an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Chardan Capital raised their price target on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Finally, Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $7.57.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.